Safety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial

Simple item page
dc.contributor.authorJamaliMoghadamSiahkali, Saeidreza
dc.contributor.authorZarezade, Besharat
dc.contributor.authorKoolaji, Sogol
dc.contributor.authorSeyedAlinaghi, SeyedAhmad
dc.contributor.authorZendehdel, Abolfazl
dc.contributor.authorTabarestani, Mohammad
dc.contributor.authorSekhavati Moghadam, Ehsan
dc.contributor.authorAbbasian, Ladan
dc.contributor.authorDehghan Manshadi, Seyed A.
dc.contributor.authorSalehi, Mohamadreza
dc.contributor.authorHasannezhad, Malihe
dc.contributor.authorGhaderkhani, Sara
dc.contributor.authorMeidani, Mohsen
dc.contributor.authorSalahshour, Faeze
dc.contributor.authorJafari, Fatemeh
dc.contributor.authorManafi, Navid
dc.contributor.authorGhiasvand, Fereshteh
dc.date.accessioned2021-03-01T05:20:59Z
dc.date.issued2021-02-11
dc.date.updated2021-03-01T05:20:59Z
dc.description.abstractAbstract Background Vitamin C is an essential water-soluble nutrient that functions as a key antioxidant and has been proven to be effective for boosting immunity. In this study, we aimed to assess the efficacy of adding high-dose intravenous vitamin C (HDIVC) to the regimens for patients with severe COVID-19 disease. Methods An open-label, randomized, and controlled trial was conducted on patients with severe COVID-19 infection. The case and control treatment groups each consisted of 30 patients. The control group received lopinavir/ritonavir and hydroxychloroquine and the case group received HDIVC (6 g daily) added to the same regimen. Results There were no statistically significant differences between two groups with respect to age and gender, laboratory results, and underlying diseases. The mean body temperature was significantly lower in the case group on the 3rd day of hospitalization (p = 0.001). Peripheral capillary oxygen saturations (SpO2) measured at the 3rd day of hospitalization was also higher in the case group receiving HDIVC (p = 0.014). The median length of hospitalization in the case group was significantly longer than the control group (8.5 days vs. 6.5 days) (p = 0.028). There was no significant difference in SpO2 levels at discharge time, the length of intensive care unit (ICU) stay, and mortality between the two groups. Conclusions We did not find significantly better outcomes in the group who were treated with HDIVC in addition to the main treatment regimen at discharge. Trial registration irct.ir (IRCT20200411047025N1), April 14, 2020
dc.identifier.citationEuropean Journal of Medical Research. 2021 Feb 11;26(1):20
dc.identifier.urihttps://doi.org/10.1186/s40001-021-00490-1
dc.identifier.urihttp://hdl.handle.net/1993/35339
dc.language.rfc3066en
dc.rightsopen accessen_US
dc.rights.holderThe Author(s)
dc.titleSafety and effectiveness of high-dose vitamin C in patients with COVID-19: a randomized open-label clinical trial
dc.typeJournal Article
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
40001_2021_Article_490.pdf
Size:
1.03 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
2.24 KB
Format:
Item-specific license agreed to upon submission
Description:
Download
Collections
University of Manitoba Scholarship
Rady Faculty of Health Sciences Scholarly Works